Dong OM, Friede KA, Chanfreau-Coffinier C, Voora D. Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. Eur Heart J Qual Care Clin Outcomes. 2023 Apr 26;9(3):249-57. doi: 10.1093/ehjqcco/qcac031
Song W, Musetti SN, Huang L. Nanomaterials for cancer immunotherapy. Biomaterials. 2017 Dec;148:16-30. doi: 10.1016/j.biomaterials
Luo C, Miao L, Zhao Y, Musetti S, Wang Y, Shi K, Huang L. A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials. 2016 Sep;102:239-48. doi: 10.1016/j.biomaterials.2016.06.030
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.